Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi


Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101762


Historical Background

Phosphatidylethanolamine-binding protein 1 (PEBP-1) was first isolated as a cytosolic, 23 kDa protein from bovine brain and was also found in soluble extracts from human platelets and rodent brains (Bernier and Jolles 1984). A series of studies over the next decade led to its identification as the precursor for hippocampal cholinergic neurostimulating peptide (HCNP), an acetylated eleven amino acid long peptide conserved in the rat, human, and bovine genome (Tohdoh et al. 1995). Although, it was originally named for its binding affinity for the phospholipid phosphatidylethanolamine, a breakthrough report characterized PEBP-1 as a Raf-1 kinase binding protein with the ability to inhibit the mitogen-activated protein kinase (MAPK) pathway; hence the name Raf kinase inhibitory protein (RKIP) (Yeung et al. 1999). These seminal studies catalyzed a growth of interest for PEBP-1/RKIP, and since then PEBP-1/RKIP has been implicated in a myriad of cellular and physiological processes by way of its privileged position in various signaling pathways.

Structure and Expression

In humans, pebp-1 is located on chromosome 12q24.23. Four exons encode the full-length, 187 amino acid long PEBP-1/RKIP, with the first exon encoding for HCNP. The sequence of HCNP is acetyl-Ala-Ala-Asp-Ile-Ser-Gln-Trp-Ala-Gly-Pro-Leu. Its release in the hippocampus was found to be dependent on NMDA receptor activation (Ojika et al. 2000). The promoter of pebp-1/rkip lacks a TATA box and instead uses CpG islands, a common feature of housekeeping genes (Okita et al. 2009). There are also enhancer elements within the promoter from positions −596 to −417 relative to the TSS. In mammals and under basal conditions, PEBP-1/RKIP is expressed in virtually all tissues of the body. However, the highest levels are present in the testis, brain, and adrenal gland (Frayne et al. 1999; Uhlén et al. 2015). Levels of PEBP-1/RKIP in the brain are considerably lower during embryonic development compared to adulthood, and decline again at old age (Frayne et al. 1999). Using a mouse strain carrying a β-geo reporter, Theroux and colleagues characterized PEBP-1/RKIP expression in the adult brain and found the highest levels in limbic structures (hypothalamus, hippocampus, nucleus accumbens, amygdala) as well as cerebellar Purkinje cells and olfactory neurons (Theroux et al. 2007). PEBP-1/RKIP knock out mice display a progressive olfaction deficit starting at four months of age (Theroux et al. 2007).

Although structurally compact, the PEBP-1/RKIP protein has some outstanding properties that likely contribute to its functional diversity. PEBP-1/RKIP contains a ligand-binding pocket that is similar to conserved phospholipid-interacting domains present in other PEBP family members. PEBP-1/RKIP is capable of binding to phospholipids in in vitro assays, but whether or not this interaction occurs in vivo remains unclear (Skinner and Rosner 2014). The pocket loop has been shown to bind nucleotides, and there is significant evidence that this subregion as well as neighboring residues mediate binding to signaling molecules such as Raf-1 (Tavel et al. 2012). Five phosphorylation sites on PEBP-1/RKIP have been identified thus far: threonine-42, serine-52, serine-54, serine-99, and serine-153. The most highly characterized phosphorylation at ser-153 has been shown to trigger further structural changes leading to PEBP-1/RKIP homodimerization, which in turn controls its binding specificity for other protein partners (Deiss et al. 2012). However, we are just beginning to understand the functional contributions of these modifications.

Roles in Cell Signaling

The first and best-characterized role of PEBP-1/RKIP in cell signaling is in the ubiquitous MAPK pathway (Fig. 1). Upon receptor tyrosine kinase (RTK) activation by a growth factor, the monomeric G protein Ras initiates a phosphorylation cascade that involves the sequential kinases Raf-1, MAPK/ERK kinase (MEK), and extracellular signal-regulated protein kinase (ERK). PEBP-1/RKIP is the only known inhibitor of Raf-1, and it exerts its effects by physically interacting with Raf-1 or, alternatively, MEK to disrupt downstream MAPK/ERK signaling (Yeung et al. 2000) (Fig. 1a). PEBP-1/RKIP can also regulate G-protein coupled receptor (GPCR) signaling via interaction with GPCR kinase 2 (GRK2), a protein that promotes agonist-induced receptor internalization and desensitization. GPCR activation leads to protein kinase C (PKC)-mediated phosphorylation of PEBP-1/RKIP at ser-153, a phospho switch that triggers its dissociation from Raf-1 and promotes its subsequent binding to GRK2 (Lorenz et al. 2003) (Fig. 1b). Furthermore, PEBP-1/RKIP was also found to antagonize nuclear factor kappa B (NF-κB) signaling (Yeung et al. 2001) (Fig. 2). NF-κB is a transcription factor that is sequestered in the cytoplasm in a latent or inactive state by proteins called inhibitors of κB (IκB). Phosphorylation of IκBs by the IκB kinase complex (IKK) targets them for degradation, thereby liberating NF-κB, which then translocates to the nucleus and regulates gene transcription (Fig. 2a). A diverse array of protein kinases can activate the IKK complex, and it is at this level that PEBP-1/RKIP acts to prevent NF-κB signaling. By interacting with transforming growth factor beta-activated kinase (TAK1) and NF-κB-inducing kinase (NIK), PEBP-1/RKIP inhibits their ability to activate IKK (Yeung et al. 2001) (Fig. 2b). PEBP-1/RKIP also regulates the activity of glycogen synthase kinase-3β (GSK3β), a protein involved in multiple signaling pathways including the canonical Wnt pathway, where it acts as an inhibitor of β-catenin signaling (Fig. 3a) (Al-Mulla et al. 2011a). PEBP-1/RKIP binds GSK3β and is required to maintain normal GSK3β protein levels (Fig. 3c). Furthermore, PEBP-1/RKIP suppresses the phosphorylation of GSK3β at thr-390, an inhibitory site that is targeted by the MAPK p38 (Fig. 3b, c) (Al-Mulla et al. 2011a).
PEBP-1, Fig. 1

Schematic diagram of the role of PEBP-1/RKIP in the MAPK/ERK pathway and its interaction with GRK2 and GPCR signaling. A receptor tyrosine kinase (RTK) is depicted in blue, while a G-protein coupled receptor (GPCR) is shown in green. (a) PEBP-1/RKIP binds to Raf-1 and MEK, inhibiting downstream ERK activation. GRK2 is inhibiting GPCR signaling (thin arrow) by targeting receptors for internalization and/or degradation (thick arrow). (b) Upon GPCR receptor activation by its ligand (brown), protein kinase C (PKC) phosphorylates PEBP-1/RKIP at serine/threonine-153 (S/T153). PEBP-1/RKIP switches from binding Raf-1 and MEK, to GRK2, and can no longer suppress ERK activation. At the same time, GRK2 is no longer available to down-regulate GPCR signaling

PEBP-1, Fig. 2

PEBP-1/RKIP as a negative regulator of the NF-κB pathway. (a) NF-κB is able to translocate to the nucleus once the inhibitor of κB (IκB) is targeted for degradation by phosphorylation mediated by the inhibitor of κB kinase complex (IKK). TAK1 (transforming growth factor beta-activated kinase) and NIK (NF-κB inducing kinase) phosphorylate IKK to activate it. (b) RKIP binds to NIK1 and TAK, blocking their phosphorylation of IKK. As a consequence, IκB is not targeted for degradation and continues to be bound to NF-κB, which remains inactive in the cytoplasm

PEBP-1, Fig. 3

PEBP-1/RKIP negatively regulates the Wnt/β-catenin pathway through GSK3β. (a) Active GSK3β phosphorylates β-catenin, promoting its degradation and inhibiting downstream transcription of target genes. (b) GSK3β activity is inhibited by phosphorylation at threonine-390, a residue that is targeted by p38. As a result of GSK3β inhibition, β-catenin is stabilized and is able to induce transcription of Wnt target genes. (c) PEBP-1/RKIP is required to maintain high levels of GSK3β protein expression. It also binds to GSK3β and prevents phosphorylation at threonine-390

Roles in Cell Function

PEBP-1/RKIP plays a role in many cellular functions that are regulated by the MAPK signaling pathway. One of these is cellular senescence, a response to cell damage that is mediated by the tumor suppressor protein p53 and is accompanied by downregulation of MAPK activity. Stress due to DNA damage increases expression of p53. Phosphorylation of p53 at ser-46 triggers its transcriptional activation of the pebp-1/rkip gene (Lee et al. 2013). Furthermore, irradiated senescent tumor cells have been shown to secrete PEBP-1/RKIP, which promotes the migration of neighboring cells (Han et al. 2012). The role of PEBP-1/RKIP in cell motility and migration has been studied in different contexts, beginning with a report where the interaction between Raf-1 and PEBP-1/RKIP was shown to be disrupted by locostatin, a cell migration inhibitor (Zhu et al. 2005). In vitro silencing of PEBP-1/RKIP expression also slowed the rate of epithelial cell migration, whereas overexpressing PEBP-1/RKIP dramatically increased cell motility, conferring a fibroblast-like phenotype (Zhu et al. 2005). Other studies suggest that PEBP-1/RKIP may have a suppressive rather than facilitatory effect on cell migration. For instance, in various types of malignant tumors, expression levels of this gene are inversely correlated with metastasis (Yesilkanal and Rosner 2014). Some studies suggest that PEBP-1/RKIP may suppress cell migration and invasion through signaling networks downstream of the MAPK cascade that may involve chromatin remodeling factors and micro-RNAs (Yesilkanal and Rosner 2014). In another in vitro model using human embryonic cell lines, PEBP-1/RKIP was suggested to suppress cell motility by inhibiting the expression or stability of p21-activated protein kinase 1 (PAK1), β-catenin, and vimentin (Al-Mulla et al. 2011b). In the same study, a role for PEBP1/RKIP in cellular proliferation was investigated. Depleting cells of pebp1/rkip expression lead to an increase in cell division, by overriding mitotic checkpoints and accelerating progression through G1/S and G2/M (Al-Mulla et al. 2011b). PEBP-1/RKIP also plays a role in determining cell fate in neural lineages, as observed in vitro using neuroblastoma cell lines (Hellmann et al. 2010). Although the mechanisms are yet to be elucidated, silencing PEBP-1/RKIP promotes a glial phenotype, whereas its overexpression tips the balance toward a neuronal fate (Hellmann et al. 2010).

Physiological Functions

In various tissue and cell types, PEBP-1/RKIP expression contributes to their normal functioning, but it may also have deleterious effects under pathological conditions. For example, by regulating β-adrenergic signaling at the level of β1 and β2 receptors in the heart, PEBP-1/RKIP improves cardiac contractility and has antiapoptotic and antifibrotic effects (Schmid et al. 2015). In contrast, PEBP-1/RKIP expression has a negative effect in a mouse model for systemic inflammatory response syndrome (SIRS), a common cause for complications in hospitalized patients. SIRS develops due to an exaggerated release of proinflammatory cytokines. PEBP-1/RKIP reportedly exacerbates this cytokine storm by driving the overproduction of one such cytokine, interferon gamma (IFN-γ), by CD8+ T cells (Wright and Vella 2013).

PEBP-1/RKIP and its derivatives have also been found to play roles in brain function and pathologies. The HCNP peptide stimulates acetylcholine synthesis in the medial septal nucleus by increasing the expression of the enzyme choline acetyltransferase (ChAT) . Overexpressing the precursor protein in murine forebrain neurons leads to a depressive-like phenotype specifically at old age, while overall normal cognitive function is maintained (Matsukawa et al. 2010). Long-term depression (LTD) is another instance where the modulation of the MAPK pathway by PEBP-1/RKIP shapes a physiological function. LTD can be induced in vivo and ex vivo in specific neural circuits, among them the input from the parallel and climbing fibers, to Purkinje cells in the cerebellum. LTD is an electrophysiological phenomenon where short patterns of neural activity have a long-lasting inhibitory effect. Such plasticity requires intracellular calcium release, PKC, and persistent MAPK activity. A study by Yamamoto and collaborators found that phosphorylation of PEBP-1/RKIP by PKC is required to disrupt its interaction with Raf-1 or MEK, promoting persistent MAPK activity (Yamamoto et al. 2012). More recently, a role in long-term potentiation (LTP) was also reported. LTP is the long-lasting facilitation in a neural circuit following a short pattern of activity. LTP in the Schaffer collateral of the hippocampus was investigated by Ohi and collaborators in a murine model. They found that overexpression of PEBP-1/RKIP led to enhancement of LTP, possibly through the action of acetylcholine muscarinic receptors at glutamatergic postsynapses (Ohi et al. 2015).

In mammals, the clock cells of the suprachiasmatic nucleus (SCN), the hypothalamic region responsible for maintaining circadian (∼24 h) rhythmicity, rely on MAPK signaling to synchronize with the environment. In these cells, synchronized and self-sustained daily rhythms in transcription and translation of clock genes such as Period1/2 can be reset by external time cues. Light-induced Period transcription depends on the rapid and transient activation of MAPK/ERK in SCN neurons, leading to a shift in the clock phase as the SCN realigns to match environmental time. In the absence of PEBP-1/RKIP, light-induced MAPK activity in the SCN is prolonged, and the phase-shifting response to light stimuli is consequently exaggerated (Antoun et al. 2012). However, the role of PEBP-1/RKIP in circadian rhythms is yet to be examined in relation to other signaling regulators such as GRKs.

A potential involvement of PEBP-1/RKIP in Alzheimer’s disease (AD) has also been suggested. When investigated in postmortem brains of AD patients, the protein was found to be expressed in Hirano bodies, a neuropathological component of the disease (Ojika et al. 2000).

The role of PEBP-1/RKIP in cancer has been extensively investigated. Many clinical studies have reported downregulation in PEBP-1/RKIP expression in solid tumors of the prostate, breast, colon/rectum, esophagus, stomach, ovary, cervix, liver, kidney, lung, nasopharynx, and brain, as well as cancers of the bone marrow and blood (Lamiman et al. 2014). The relationship between RKIP and tumorigenesis was first studied in prostate cancer, where low PEBP-1/RKIP expression correlated with cancer metastasis and a higher rate of cancer recurrence (Fu et al. 2006). Similar results have been found in other tumor types. Clinical results suggest that PEBP-1/RKIP may be a useful prognostic marker for metastasis, overall survival, and disease-free survival (Lamiman et al. 2014). However, this cannot be generalized to all cancers, as loss of PEBP-1/RKIP appears to be a favorable prognostic indicator for patients with acute myeloid leukemia (Zebisch et al. 2012). The mechanism for loss of PEBP-1/RKIP expression in human cancers is unclear, although gene silencing through promoter methylation is believed to be a contributing factor in some cancer types (Li et al. 2014). Collectively, these findings have cemented PEBP-1/RKIP’s reputation as a metastasis supressor, but also as a potential biomarker for disease prognosis (Lamiman et al. 2014).


First identified as the precursor for HCNP, PEBP-1/RKIP is an evolutionarily conserved, small, and compact protein. Its structure displays a versatile binding pocket that allows it to interact with various molecules to influence multiple signaling pathways. PEBP-1/RKIP is best known for its role as an inhibitor of MAPK signaling through its interaction with Raf-1, but it also modulates GRK2, NF-κB, and GSK3β. Other reported roles are in cell cycle progression, differentiation, migration, and apoptosis. It also contributes to many physiological functions at the organismal level, including neural development and plasticity, circadian rhythms, immune response, cardiac function, and others. Finally, its expression impacts the development and progression of various diseases, not the least of which is cancer. However, many outstanding questions remain, including how pebp-1/rkip expression is regulated, which downstream signaling pathways are relevant to its effects in the various physiological systems or disease states studied so far, and whether there are additional signaling pathways that are under its regulation.

PEBP-1/RKIP has emerged as a novel class of cell signaling “gatekeeper” that maintains homeostasis by interacting with key signaling effectors and preventing them from throwing the physiological state off balance. Furthermore, PEBP-1/RKIP seems to be a convergence node for various signaling pathways to cross-talk and influence each other. The strategic positioning of PEBP-1/RKIP could be a mechanism by which context-dependent response specificity is achieved.


  1. Al-Mulla F, Bitar MS, Al-Maghrebi M, Behbehani AI, Al-Ali W, Rath O, et al. Raf kinase inhibitor protein RKIP enhances signaling by glycogen synthase kinase-3β. Cancer Res. 2011a;71(4):1334–43.PubMedCrossRefGoogle Scholar
  2. Al-Mulla F, Bitar MS, Taqi Z, Rath O, Kolch W. RAF kinase inhibitory protein (RKIP) modulates cell cycle kinetics and motility. Mol Biosyst. 2011b;7:928–41.PubMedCrossRefGoogle Scholar
  3. Antoun G, Bouchard-Cannon P, Cheng H-YM. Regulation of MAPK/ERK signaling and photic entrainment of the suprachiasmatic nucleus circadian clock by raf kinase inhibitor protein. J Neurosci. 2012;32(14):4867–77.PubMedPubMedCentralCrossRefGoogle Scholar
  4. Bernier I, Jolles P. Purification and characterization of a basic 23 kDa cytosolic protein from bovine brain. Biochim Biophys Acta (BBA)/Protein Struct Mol. 1984;790(2):174–81.CrossRefGoogle Scholar
  5. Deiss K, Kisker C, Lohse MJ, Lorenz K. Raf kinase inhibitor protein (RKIP) dimer formation controls its target switch from Raf1 to G protein-coupled receptor kinase (GRK) 2. J Biol Chem. 2012;287(28):23407–17.PubMedPubMedCentralCrossRefGoogle Scholar
  6. Frayne J, Ingram C, Love S, Hall L. Localisation of phosphatidylethanolamine-binding protein in the brain and other tissues of the rat. Cell Tissue Res. 1999;298(3):415–23.PubMedCrossRefGoogle Scholar
  7. Fu Z, Kitagawa Y, Shen R, Shah R, Mehra R, Rhodes D, et al. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate. 2006;66(3):248–56.PubMedCrossRefGoogle Scholar
  8. Han NK, Kim BC, Lee HC, Lee YJ, Park MJ, Chi SG, et al. Secretome analysis of ionizing radiation-induced senescent cancer cells reveals that secreted RKIP plays a critical role in neighboring cell migration. Proteomics. 2012;12(18):2822–32.PubMedCrossRefGoogle Scholar
  9. Hellmann J, Rommelspacher H, Mühlbauer E, Wernicke C. Raf kinase inhibitor protein enhances neuronal differentiation in human SH-SY5Y cells. Dev Neurosci. 2010;32(1):33–46.PubMedCrossRefGoogle Scholar
  10. Lamiman K, Keller JM, Mizokami A, Zhang J, Keller ET. Survey of Raf kinase inhibitor protein (RKIP) in multiple cancer types. Crit Rev Oncog. 2014;19(6):455–68.PubMedCrossRefGoogle Scholar
  11. Lee S-J, Lee S-H, Yoon M-H, Park B-J. A new p53 target gene, RKIP, is essential for DNA damage-induced cellular senescence and suppression of ERK activation. Neoplasia. 2013;15(7):727–37.PubMedPubMedCentralCrossRefGoogle Scholar
  12. Li D, Cai H, Wang X, Feng Y, Cai S. Promoter methylation of Raf kinase inhibitory protein: a significant prognostic indicator for patients with gastric adenocarcinoma. Exp Ther Med. 2014;8(3):844–50.PubMedPubMedCentralCrossRefGoogle Scholar
  13. Lorenz K, Lohse MJ, Quitterer U. Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature. 2003;426(6966):574–9.PubMedCrossRefGoogle Scholar
  14. Matsukawa N, Furuya Y, Ogura H, Ojika K. HCNP precursor protein transgenic mice display a depressive-like phenotype in old age. Brain Res. 2010;1349:153–61.PubMedCrossRefGoogle Scholar
  15. Ohi Y, Kato D, Mizuno M, Sato T, Ueki Y, Borlongan CV, et al. Enhancement of long-term potentiation via muscarinic modulation in the hippocampus of HCNP precursor transgenic mice. Neurosci Lett. 2015;597:1–6.PubMedCrossRefGoogle Scholar
  16. Ojika K, Mitake S, Tohdoh N, Appel SH, Otsuka Y, Katada E, et al. Hippocampal cholinergic neurostimulating peptides (HCNP). Prog Neurobiol. 2000;60(1):37–83.PubMedCrossRefGoogle Scholar
  17. Okita K, Matsukawa N, Maki M, Nakazawa H, Katada E, Hattori M, et al. Analysis of DNA variations in promoter region of HCNP gene with Alzheimer’s disease. Biochem Biophys Res Commun. 2009;379(2):272–6.PubMedCrossRefGoogle Scholar
  18. Schmid E, Neef S, Berlin C, Tomasovic A, Kahlert K, Nordbeck P, et al. Cardiac RKIP induces a beneficial β-adrenoceptor-dependent positive inotropy. Nat Med. 2015;21(11):1298–306.PubMedCrossRefGoogle Scholar
  19. Skinner JJ, Rosner MR. RKIP structure drives its function: a three-state model for regulation of RKIP. Crit Rev Oncog. 2014;19(6):483–8.PubMedPubMedCentralCrossRefGoogle Scholar
  20. Tavel L, Jaquillard L, Karsisiotis AI, Saab F, Jouvensal L, Brans A, et al. Ligand binding study of human PEBP1/RKIP: Interaction with nucleotides and raf-1 peptides evidenced by NMR and mass spectrometry. PLoS One. 2012;7(4):e36187.PubMedPubMedCentralCrossRefGoogle Scholar
  21. Theroux S, Pereira M, Casten KS, Burwell RD, Yeung KC, Sedivy JM, et al. Raf kinase inhibitory protein knockout mice: expression in the brain and olfaction deficit. Brain Res Bull. 2007;71:559–67.PubMedCrossRefGoogle Scholar
  22. Tohdoh N, Tojo S, Agui H, Ojika K. Sequence homology of rat and human HCNP precursor proteins, bovine phosphatidylethanolamine-binding protein and rat 23-kDa protein associated with the opioid-binding protein. Brain Res Mol Brain Res. 1995;30(2):381–4.PubMedCrossRefGoogle Scholar
  23. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Tissue-based map of the human proteome. Science. 2015;347(6220):394.CrossRefGoogle Scholar
  24. Wright KT, AT V. RKIP contributes to IFN- synthesis by CD8+ T cells after serial TCR triggering in systemic inflammatory response syndrome. J Immunol. 2013;191:708–16.PubMedPubMedCentralCrossRefGoogle Scholar
  25. Yamamoto Y, Lee D, Kim Y, Lee B, Seo C, Kawasaki H, et al. Raf kinase inhibitory protein is required for cerebellar long-term synaptic depression by mediating PKC-dependent MAPK activation. J Neurosci. 2012;32(41):14254–64.PubMedCrossRefGoogle Scholar
  26. Yesilkanal AE, Rosner MR. Raf kinase inhibitory protein (RKIP) as a metastasis suppressor: regulation of signaling networks in cancer. Crit Rev Oncog. 2014;19(6):447–54.PubMedPubMedCentralCrossRefGoogle Scholar
  27. Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, et al. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature. 1999;401(6749):173–7.PubMedCrossRefGoogle Scholar
  28. Yeung K, Janosch P, McFerran B, Rose DW, Mischak H, Sedivy JM, et al. Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol. 2000;20(9):3079–85.PubMedPubMedCentralCrossRefGoogle Scholar
  29. Yeung K, Rose DW, Dhillon AS, Yaros D, Gustafsson M, Chatterjee D, et al. Raf kinase inhibitor protein interacts with NF-κ B-inducing kinase and TAK1 and inhibits NF-κ B activation. Mol Cell Biol. 2001;21(21):7207–17.PubMedPubMedCentralCrossRefGoogle Scholar
  30. Zebisch A, Wölfler A, Fried I, Wolf O, Lind K, Bodner C, et al. Frequent loss of RAF kinase inhibitor protein expression in acute myeloid leukemia. Leukemia. 2012;26(8):1842–9.PubMedCrossRefGoogle Scholar
  31. Zhu S, Mc Henry KT, Lane WS, Fenteany G. A chemical inhibitor reveals the role of Raf kinase inhibitor protein in cell migration. Chem Biol. 2005;12(9):981–91.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Department of BiologyUniversity of Toronto MississaugaMississaugaCanada
  2. 2.Department of Cell and Systems BiologyUniversity of TorontoTorontoCanada